15 results on '"Kelly, Virginia"'
Search Results
2. Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
3. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
4. Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part A (pembrolizumab alone).
5. Predictors of treatment response in colorectal high-grade neuroendocrine carcinomas (HGNEC): A single institution experience.
6. Outcomes after cessation of therapy with alkylating agents (AA) for pancreatic neuroendocrine tumors (panNETs).
7. Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
8. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability
9. High frequency mismatch repair (MMR) pathway mutations in adrenocortical carcinoma: Indication for routine MMR-deficiency (MMR-D) testing.
10. Widespread somatic loss of heterozygosity as a possible marker of disease aggressiveness in metastatic well differentiated pancreatic neuroendocrine tumors.
11. A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin.
12. A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi).
13. Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor.
14. Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL.
15. Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.